The androgen receptor (AR) and the factors that transactivate the AR appear to have the greatest impact on the development and progression of prostate cancer. The removal of androgen by combined androgen blockade does not necessarily mean that the AR signaling pathway is silent and therefore not involved in the progression to androgen-independent disease. We have developed a primary, human prostate epithelial cell transfection assay that can measure the biological activity of the androgen receptor (AR) directly in these cells during the progression from androgen-dependent to androgen-independent growth. The HYPOTHESIS of this study is that the development of androgen-independent prostate cancer is modulated either through AR/co-regulator interactions or through the interactions of other factors which can bind directly to the same AR DNA binding site.
The SPECIFIC AIMS of this study are: I. Characterizing the biological activity of the AR in primary HPE cells which represent the progression to androgen-independence. II. Isolating co-regulators from primary HPE cells that bind to AR or to ARBS-2 directly. III. Defining the cooperative interaction of the identified co-regulators with AR or ARBS-2. Our long term goals are to elucidate the mechanisms that govern the switch to androgen-independent human prostate cancer. The molecular mechanisms by which transactivation of the AR facilitates the development of androgen-independence prostate cancer could translate into valuable tools in the clinic as markers for prognosis, provide an assay for predicting hormonal responsiveness to androgen deprivation, and provide potential targets for novel therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK060957-01A2
Application #
6682247
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Margolis, Ronald N
Project Start
2003-07-15
Project End
2008-05-31
Budget Start
2003-07-15
Budget End
2004-05-31
Support Year
1
Fiscal Year
2003
Total Cost
$319,547
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Surgery
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Zhou, Jian; Kasper, Susan; Papautsky, Ian (2013) Enhanced size-dependent trapping of particles using microvortices. Microfluid Nanofluidics 15:
Zhou, Jian; Giridhar, Premkumar Vummidi; Kasper, Susan et al. (2013) Modulation of aspect ratio for complete separation in an inertial microfluidic channel. Lab Chip 13:1919-29
Williams, Karin; Motiani, Karan; Giridhar, Premkumar Vummidi et al. (2013) CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 238:324-38
Williams, Karin; Ghosh, Ritwik; Giridhar, Premkumar Vummidi et al. (2012) Inhibition of stathmin1 accelerates the metastatic process. Cancer Res 72:5407-17
Kasper, Susan (2009) Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol Oncol 27:301-3
Kasper, Susan (2008) Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 4:193-201
Kasper, Susan (2008) Stem cells: The root of prostate cancer? J Cell Physiol 216:332-6
Chaurand, Pierre; Rahman, Mohammad A; Hunt, Tamela et al. (2008) Monitoring mouse prostate development by profiling and imaging mass spectrometry. Mol Cell Proteomics 7:411-23
Gu, Guangyu; Yuan, Jialing; Wills, Marcia et al. (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67:4807-15
Tillman, J Erin; Yuan, Jialing; Gu, Guangyu et al. (2007) DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 67:4630-7

Showing the most recent 10 out of 14 publications